Virginia Cancer Specialists is pleased to share a new episode of OncoTalks featuring our own Dr. Alexander I. Spira, MD, PhD, FACP, FASCO—Co-Director of the Virginia Cancer Specialists Research Institute and Director of the Thoracic and Phase I Program. In this episode, host Dr. Ira Zackon joins Dr. Spira for an in-depth discussion on the importance of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).
The conversation highlights key findings from a recent study showing variability in biomarker testing practices and underscores the value of comprehensive DNA- and RNA-based next-generation sequencing over single-gene testing. Viewers will also hear a review of current clinical guidelines, learn how biomarker testing impacts treatment sequencing, and gain insights into how community oncology practices can overcome barriers to ensure all NSCLC patients receive guideline-concordant testing and treatment.
Developed and produced by Ontada Learn. This content is intended for educational purposes and reflects current research and expert opinion as of the release date.
Learn more here (or click below)
Related Posts
Recent Posts
